Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A, Léonce S, Kraus-Berthier L, Bal-Mahieu C, Mazinghien R, Didier S, David-Cordonnier MH, Hautefaye P, Lavielle G, Bailly C, Hickman JA, Pierré A. Lansiaux A, et al. Among authors: bal mahieu c. Mol Pharmacol. 2007 Aug;72(2):311-9. doi: 10.1124/mol.107.034637. Epub 2007 May 9. Mol Pharmacol. 2007. PMID: 17494837
New selective carbonic anhydrase IX inhibitors: synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides.
Rogez-Florent T, Meignan S, Foulon C, Six P, Gros A, Bal-Mahieu C, Supuran CT, Scozzafava A, Frédérick R, Masereel B, Depreux P, Lansiaux A, Goossens JF, Gluszok S, Goossens L. Rogez-Florent T, et al. Among authors: bal mahieu c. Bioorg Med Chem. 2013 Mar 15;21(6):1451-64. doi: 10.1016/j.bmc.2012.10.029. Epub 2012 Oct 29. Bioorg Med Chem. 2013. PMID: 23168081
Lamellarin D: a novel potent inhibitor of topoisomerase I.
Facompré M, Tardy C, Bal-Mahieu C, Colson P, Perez C, Manzanares I, Cuevas C, Bailly C. Facompré M, et al. Among authors: bal mahieu c. Cancer Res. 2003 Nov 1;63(21):7392-9. Cancer Res. 2003. PMID: 14612538
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, Robin YM, Bay JO, Piperno-Neumann S, Blay JY, Fournier C. Penel N, et al. Among authors: bal mahieu c. Target Oncol. 2014 Sep;9(3):273-7. doi: 10.1007/s11523-013-0299-0. Epub 2013 Nov 12. Target Oncol. 2014. PMID: 24218035 Clinical Trial.